Analyst Tim Anderson from Bank of America Securities reiterated a Hold rating on Pfizer (PFE – Research Report) and decreased the price target to $26.00 from $29.00.
Tim Anderson has given his Hold rating due to a combination of factors affecting Pfizer’s stock. One key reason is the uncertainty surrounding the long-term growth prospects of Pfizer’s major franchises, which face challenges from upcoming patent expirations and competitive pressures. This uncertainty contributes to a below-average growth outlook for the company.
Additionally, while Pfizer’s current price-to-earnings ratio and high dividend yield provide some support for the stock price, the overall valuation is impacted by broader industry concerns, such as tariffs and drug pricing issues. These factors, combined with only minor adjustments to revenue and earnings estimates, underpin the decision to maintain a Neutral rating with a price objective of $26.
In another report released on April 15, TD Cowen also maintained a Hold rating on the stock with a $32.00 price target.